Not for commercial use. Solely to be used for the educational purposes of research and open discussion.
|
Bio-Terrorism.Info EXPANDED REPORTING; Pg. 4 January 13, 2003
"This contract builds on our preclinical data showing that CpG oligos protect mice against a broad range of pathogens, including anthrax, as well as our human clinical data showing enhancement of the Engerix-B Hepatitis B vaccine when combined with our immunostimulatory oligos," said Robert L. Bratzler, PhD, Coley president and CEO. "The DARPA contract and other development agreements with our partners, including Aventis and GlaxoSmithKline, give Coley the opportunity to realize the full potential of its immunostimulatory oligos to prevent or treat a broad range of diseases." The current anthrax vaccine requires six doses and 18 months to produce immunity. Coley's CpG oligos, used together with vaccines, have the potential to reduce the number of vaccine doses, induce protective antibody levels more quickly, produce higher affinity antibodies directed against a broader range of anthrax antigens, and to improve duration of protection. This research at Coley stems from a grant awarded in 1999 to Arthur Krieg, MD, then a professor of Internal Medicine at the University of Iowa, a Coley founder and currently the company's Chief Scientific Officer. Commenting on this new contract, Krieg said, "I am delighted that our progress since we began this program in 1999 has been so rapid, and that DARPA has selected this program to transition from the preclinical phase to the clinical phase as a high priority."
|
Coley has specifically optimized CpG 10103, a B Class oligo for vaccine applications. CpG 10103, acting through the TLR9 receptor present in B-cells and plasmacytoid dendritic cells, potently stimulates human B-cell proliferation, enhances antigen-specific antibody production and induces Interferon-alpha production, Interleukin-10 secretion, and Natural Killer Cell (NK cell) activity. These broad immunostimulatory actions are required to improve the immune response to vaccines.
The approved dosing of Engerix-B requires three vaccinations over 6 months but fails to induce protective antibody levels in 5-10% of normal healthy individuals. In a clinical study conducted by Coley in normal healthy volunteers, individuals given the Engerix-B vaccine (without CpG 7909) rarely had any detectable antibody response within 2 weeks of the first vaccine dose, but almost 60% of subjects given the vaccine together with CpG 7909 had protective antibody levels within just 2 weeks of the first dose, and 100% of subjects receiving CpG 7909 did within 6 weeks. This article was prepared by Bio-Terrorism.Info editors from staff and other reports. http://www.NewsRx.net |
Perhaps people don't want to consider the fact that Bush Sr. sparked Saddam's enmity by stumbling into a war that could have been averted. Saddam was a de facto ally prior to 1990. Since 1991, he has been a great source of mischief and death for Americans.
And you can thank Bush Sr. for that.
Think back. Saddam attacked Iran in 1980 and siezed some of the oil refineries right across the border. He --thought-- the Iranians, racked by revolution, were an easy target. He was wrong. Eight years and as many as 500,000 KIA later, the war ended.
Remember this: The Reagan administration supported BOTH sides in this war. We gave Iraq satelite intelligence at least, and we, as is known, provided Iran with TOW anti-tank missiles, helicopter parts and other aid. Now, while we were helping Iraq fight off their their deadly and militant enemy, was Saddam attacking U.S. targets? I don't remember that, do you? The war ended in 1988 in a stalemate. Do you recall any attacks on U.S. interests by Iraq in 1988, 89 or 1990? I don't.
Walt